Xu Lu, Lv Xiaozhen, Wang Huali, Liu Qingjing, Zhou Shuzhe, Gao Shuangqing, Yu Xin, Deng Siwei, Wang Shengfeng, Chang Zheng, Zhan Siyan
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Beijing Dementia Key Lab, Dementia Care & Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.
Front Psychiatry. 2021 Aug 25;12:727453. doi: 10.3389/fpsyt.2021.727453. eCollection 2021.
Psychotropic medications are commonly used for treating mental disorders; however, there is currently no study on how commonly they are used in China. This study reported the trends in psychotropic medications prescriptions in urban China. A national population-based study was conducted using the China Health Insurance Research Association database to estimate the period prescription prevalence of 11 major classes of psychotropic medications annually during 2013-2017. The World Health Organization Anatomical Therapeutic Chemical (ATC) classification codes were used to identify psychotropic medications. The prescription prevalence of any psychotropic medication increased from 8.110% (8.106-8.114%) in 2013 to 11.362% (11.357-11.366%) in 2017. The prescription prevalence of six classes increased significantly during 2013-2017, including sedatives-hypnotics (from 3.177 to 5.388%), anxiolytics (from 1.436 to 2.200%), antiepileptic drugs (from 1.416 to 2.140%), antipsychotics (from 0.809 to 1.156%), antidepressants (from 0.891 to 1.045%), and psycholeptic polypills (from 0.682 to 0.866%). The prescription prevalence of antidementia drugs increased from 0.069 to 0.122%, and mood stabilizers increased from 0.029 to 0.037%, although not statistically significant. The prescription prevalence of nootropic drugs, attention deficit hyperactivity disorder (ADHD) medications and drugs used in the treatment of addictive disorders was largely stable. Psychotropic medication prescription increased with age for all classes except for ADHD medications and mood stabilizers. Increasing trends in prescription prevalence were observed for most classes of psychotropic medications in urban China, although the prevalence was still lower than that in most developed countries. Further research is warranted to explore the potential treatment gap between China and most developed countries.
精神药物常用于治疗精神障碍;然而,目前尚无关于其在中国使用频率的研究。本研究报告了中国城市地区精神药物处方的趋势。利用中国医疗保险研究会数据库进行了一项基于全国人口的研究,以估计2013 - 2017年期间每年11大类精神药物的期间处方患病率。采用世界卫生组织解剖治疗化学(ATC)分类代码来识别精神药物。任何精神药物的处方患病率从2013年的8.110%(8.106 - 8.114%)增至2017年的11.362%(11.357 - 11.366%)。2013 - 2017年期间,六类药物的处方患病率显著增加,包括镇静催眠药(从3.177%增至5.388%)、抗焦虑药(从1.436%增至2.200%)、抗癫痫药(从1.416%增至2.140%)、抗精神病药(从0.809%增至1.156%)、抗抑郁药(从0.891%增至1.045%)以及精神安定复方制剂(从0.682%增至0.866%)。抗痴呆药物的处方患病率从0.069%增至0.122%,心境稳定剂从0.029%增至0.037%,虽无统计学意义。促智药、注意力缺陷多动障碍(ADHD)药物以及用于治疗成瘾性障碍的药物的处方患病率基本稳定。除ADHD药物和心境稳定剂外,所有类别精神药物的处方随年龄增长而增加。中国城市地区大多数类别的精神药物处方患病率呈上升趋势,尽管其患病率仍低于大多数发达国家。有必要进一步开展研究,以探索中国与大多数发达国家之间潜在的治疗差距。